Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

Research Grants 23 show all


$914.3K
2009

$924.8K
2010

$173.6K
2011

$1M
2012

$865.5K
2013

Publications 4 show all

  • 1
    Dopamine/metabolism
  • 1
    Embryonic Stem Cells/metabolism
  • 1
    Gene Targeting/methods
  • 1
    Heroin/administration & dosage
  • 1
    Narcotics/administration & dosage
  • 1
    Nucleus Accumbens/drug effects
  • 1
    PPAR gamma/metabolism
  • 1
    Synaptic Transmission/physiology

Patents 930show all

  • 302
    A61K - Preparations for medical, dental, or toilet purposes
  • 91
    C07K - Peptides
  • 29
    C12Y - Enzymes
  • 28
    C07D - Heterocyclic compounds
  • 25
    A61L - Methods or apparatus for sterilising materials or objects in general
  • 16
    A61B - Diagnosis
  • 16
    C12N - Microorganisms or enzymes
  • 16
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 12
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 11
    B82Y - Specific uses or applications of nanostructures

Clinical Trials 45show all

24Phase 38Phase 26N/A3Phase 1/Phase 23Other

SEC Filings show all


119
8-K

32
10-Q

11
10-K

3
D

1
S-1

Contact Information

201 Elliott Ave
Seattle, WA 98119
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$354,800,00051-1002017-08-22Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2007-01-11$9,000,000Private EquityStanley Medical Research Institute
2016-05-17$20,000,000Post Ipo DebtOxford Finance LLC, East West Bank
2017-08-22$68,000,000Post Ipo Equity
2014-03-20$37,800,000Post Ipo Equity
2007-02-12$63,000,000Series EWashington Research Foundation, ARCH Venture Partners, Southern Cross Venture Partners, The Grosvenor Funds, Trevi Health Ventures, Aravis Ventures, Novartis Venture Fund, Stanley Medical Research Institute
2016-11-04$125,000,000Post Ipo DebtCRG L.P.
2014-03-05$32,000,000Post Ipo DebtMidCap Financial, Oxford Finance LLC

SEC Form D Funding Events

DateOfferedSoldType
2010-10-27$11,999,970$0Option to Acquire, Security to be Acquired
2010-08-13$40,000,000$0Equity
2008-09-25Unknown Unknown Other (Paper Filing)

Key Executives

  • Gregory A Demopulos
    Executive Officer, Director
  • Marcia S. Kelbon
    Executive Officer
  • Ray Aspiri
    Director
  • Thomas J Cable
    Director
  • Peter A Demopulos
    Director
  • Leroy E. Hood
    Director
  • Daniel K Spiegelman
    Director
  • Jean-philippe Tripet
    Director
  • Gregory A. Demopulos
    Executive Officer, Director
  • Thomas J. Cable
    Director
  • Peter A. Demopulos
    Director
  • Daniel K. Spiegelman
    Director